AN2 Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 16.9 million compared to USD 11.84 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.61 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.27 USD | 0.00% | -6.20% | -88.92% |
May. 16 | Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.92% | 67.71M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- ANTX Stock
- News AN2 Therapeutics, Inc.
- AN2 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023